Literature DB >> 17379584

Simultaneous analysis of cyclophosphamide, doxorubicin and doxorubicinol by liquid chromatography coupled to tandem mass spectrometry.

Robin DiFrancesco1, Jennifer J Griggs, Julie Donnelly, Robert DiCenzo.   

Abstract

A method for the simultaneous determination of cyclophosphamide (CP), doxorubicin (dox), and doxorubicinol (dol) was developed and validated to analyze 400 microL of plasma from patients receiving chemotherapeutic treatment with CP and dox. Final calibration ranges for the analytes were 0.440-60.0 microg/mL for cyclophosphamide, 7.20-984 ng/mL for dox and 3.04-104 ng/mL for dol. The samples were prepared using solid phase extraction and analyzed using a gradient separation over a Waters Symmetry C18, 2.1 by 30 mm (Milford, MA) column. Detection was achieved in positive mixed reaction monitoring mode on a triple quadrupole mass spectrometer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17379584     DOI: 10.1016/j.jchromb.2007.02.033

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  7 in total

1.  Extraction protocol and mass spectrometry method for quantification of doxorubicin released locally from prodrugs in tumor tissue.

Authors:  Stuart Ibsen; Yongxuan Su; John Norton; Eran Zahavy; Tomoko Hayashi; Stephen Adams; Wolf Wrasidlo; Sadik Esener
Journal:  J Mass Spectrom       Date:  2013-07       Impact factor: 1.982

2.  Occurrence of cyclophosphamide and epirubicin in wastewaters by direct injection analysis-liquid chromatography-high-resolution mass spectrometry.

Authors:  Cristian Gómez-Canela; Nuria Cortés-Francisco; Xavier Oliva; Cristina Pujol; Francesc Ventura; Silvia Lacorte; Josep Caixach
Journal:  Environ Sci Pollut Res Int       Date:  2012-03-01       Impact factor: 4.223

3.  Role of c-Myb in the survival of pre B-cell acute lymphoblastic leukemia and leukemogenesis.

Authors:  Purvaba J Sarvaiya; Jason R Schwartz; Claudia P Hernandez; Paulo C Rodriguez; Wayne V Vedeckis
Journal:  Am J Hematol       Date:  2012-07-05       Impact factor: 10.047

4.  Pharmacokinetic-pharmacodynamic modelling of acute N-terminal pro B-type natriuretic peptide after doxorubicin infusion in breast cancer.

Authors:  Shuang Liang; Richard C Brundage; Pamala A Jacobson; Anne Blaes; Mark N Kirstein
Journal:  Br J Clin Pharmacol       Date:  2016-06-03       Impact factor: 4.335

5.  Mer receptor tyrosine kinase is a novel therapeutic target in pediatric B-cell acute lymphoblastic leukemia.

Authors:  Rachel M A Linger; Deborah DeRyckere; Luis Brandão; Kelly K Sawczyn; Kristen M Jacobsen; Xiayuan Liang; Amy K Keating; Douglas K Graham
Journal:  Blood       Date:  2009-07-30       Impact factor: 22.113

6.  Pharmacogenetics of human carbonyl reductase 1 (CBR1) in livers from black and white donors.

Authors:  Vanessa Gonzalez-Covarrubias; Jianping Zhang; James L Kalabus; Mary V Relling; Javier G Blanco
Journal:  Drug Metab Dispos       Date:  2008-11-20       Impact factor: 3.922

7.  Angiotensin Converting Enzyme Inhibitors (ACEI) and doxorubicin pharmacokinetics in women receiving adjuvant breast cancer treatment.

Authors:  Anne Blaes; Daniel Duprez; Todd Defor; Ryan Shanley; Heather Beckwith; Tufia Haddad; David Potter; Douglas Yee; Kinjal Sanghavi; Pamala Jacobson
Journal:  Springerplus       Date:  2015-01-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.